Provider: Nature Publishing Group
Content: application/x-research-info-systems
TY  - JOUR
AU  - Slominski, A.
AU  - Tobin, D. J.
AU  - Shibahara, S.
AU  - Wortsman, J.
TI  - Melanin pigmentation in mammalian skin and its hormonal regulation
JA  - Physiol. Rev.
PY  - 2004///
VL  - 84
SP  - 1155
EP  - 1228
M3  - 10.1152/physrev.00044.2003
N1  - 10.1152/physrev.00044.2003
UR  - http://dx.doi.org/10.1152/physrev.00044.2003
ER  -

TY  - JOUR
AU  - Boissy, R. E.
AU  - Nordlund, J. J.
TI  - Molecular basis of congenital hypopigmentary disorders in humans: a review
JA  - Pigment Cell Res.
PY  - 1997///
VL  - 10
SP  - 12
EP  - 24
M3  - 10.1111/j.1600-0749.1997.tb00461.x
N1  - 10.1111/j.1600-0749.1997.tb00461.x
UR  - http://dx.doi.org/10.1111/j.1600-0749.1997.tb00461.x
ER  -

TY  - JOUR
AU  - Cummins, D. L.
TI  - Cutaneous malignant melanoma
JA  - Mayo Clin. Proc.
PY  - 2006///
VL  - 81
SP  - 500
EP  - 507
ER  -

TY  - JOUR
AU  - Haass, N. K.
AU  - Smalley, K. S.
AU  - Herlyn, M.
TI  - The role of altered cell-cell communication in melanoma progression
JA  - J. Mol. Histol.
PY  - 2004///
VL  - 35
SP  - 309
EP  - 318
M3  - 10.1023/B:HIJO.0000032362.35354.bb
N1  - 10.1023/B:HIJO.0000032362.35354.bb
UR  - http://dx.doi.org/10.1023/B:HIJO.0000032362.35354.bb
ER  -

TY  - JOUR
AU  - Miller, A. J.
AU  - Mihm, M. C.
TI  - Melanoma
JA  - N. Engl. J. Med.
PY  - 2006///
VL  - 355
SP  - 51
EP  - 65
M3  - 10.1056/NEJMra052166
N1  - 10.1056/NEJMra052166
UR  - http://dx.doi.org/10.1056/NEJMra052166
ER  -

TY  - JOUR
AU  - Clark, W. H.
TI  - A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma
JA  - Hum. Pathol.
PY  - 1984///
VL  - 15
SP  - 1147
EP  - 1165
ER  -

TY  - JOUR
AU  - Kuchelmeister, C.
AU  - Schaumburg-Lever, G.
AU  - Garbe, C.
TI  - Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients
JA  - Br. J. Dermatol.
PY  - 2000///
VL  - 143
SP  - 275
EP  - 280
M3  - 10.1046/j.1365-2133.2000.03651.x
N1  - 10.1046/j.1365-2133.2000.03651.x
UR  - http://dx.doi.org/10.1046/j.1365-2133.2000.03651.x
ER  -

TY  - JOUR
AU  - Ishihara, K.
AU  - Saida, T.
AU  - Yamamoto, A.
TI  - Updated statistical data for malignant melanoma in Japan
JA  - Int. J. Clin. Oncol.
PY  - 2001///
VL  - 6
SP  - 109
EP  - 116
M3  - 10.1007/PL00012091
N1  - 10.1007/PL00012091
UR  - http://dx.doi.org/10.1007/PL00012091
ER  -

TY  - JOUR
AU  - Gilchrest, B. A.
AU  - Eller, M. S.
AU  - Geller, A. C.
AU  - Yaar, M.
TI  - The pathogenesis of melanoma induced by ultraviolet radiation
JA  - N. Engl. J. Med.
PY  - 1999///
VL  - 340
SP  - 1341
EP  - 1348
M3  - 10.1056/NEJM199904293401707
N1  - 10.1056/NEJM199904293401707
UR  - http://dx.doi.org/10.1056/NEJM199904293401707
ER  -

TY  - JOUR
AU  - Curtin, J. A.
TI  - Distinct sets of genetic alterations in melanoma
JA  - N. Engl. J. Med.
PY  - 2005///
VL  - 353
SP  - 2135
EP  - 2147
M3  - 10.1056/NEJMoa050092
N1  - 10.1056/NEJMoa050092
UR  - http://dx.doi.org/10.1056/NEJMoa050092
ER  -

TY  - JOUR
AU  - Wellbrock, C.
AU  - Karasarides, M.
AU  - Marais, R.
TI  - The RAF proteins take centre stage
JA  - Nature Rev. Mol. Cell Biol.
PY  - 2004///
VL  - 5
SP  - 875
EP  - 885
M3  - 10.1038/nrm1498
N1  - 10.1038/nrm1498
UR  - http://dx.doi.org/10.1038/nrm1498
ER  -

TY  - JOUR
AU  - Bohm, M.
TI  - Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes
JA  - Cell Growth Differ.
PY  - 1995///
VL  - 6
SP  - 291
EP  - 302
ER  -

TY  - JOUR
AU  - Wellbrock, C.
AU  - Weisser, C.
AU  - Geissinger, E.
AU  - Troppmair, J.
AU  - Schartl, M.
TI  - Activation of p59Fyn leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling
JA  - J. Biol. Chem.
PY  - 2002///
VL  - 277
SP  - 6443
EP  - 6454
M3  - 10.1074/jbc.M110684200
N1  - 10.1074/jbc.M110684200
UR  - http://dx.doi.org/10.1074/jbc.M110684200
ER  -

TY  - JOUR
AU  - Cohen, C.
TI  - Mitogen-actived protein kinase activation is an early event in melanoma progression
JA  - Clin. Cancer Res.
PY  - 2002///
VL  - 8
SP  - 3728
EP  - 3733
ER  -

TY  - JOUR
AU  - Satyamoorthy, K.
TI  - Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation
JA  - Cancer Res.
PY  - 2003///
VL  - 63
SP  - 756
EP  - 759
ER  -

TY  - JOUR
AU  - Willmore-Payne, C.
AU  - Holden, J. A.
AU  - Tripp, S.
AU  - Layfield, L. J.
TI  - Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis
JA  - Hum. Pathol.
PY  - 2005///
VL  - 36
SP  - 486
EP  - 493
ER  -

TY  - JOUR
AU  - Davies, H.
TI  - Mutations of the BRAF gene in human cancer
JA  - Nature
PY  - 2002///
VL  - 417
SP  - 949
EP  - 954
M3  - 10.1038/nature00766
N1  - 10.1038/nature00766
UR  - http://dx.doi.org/10.1038/nature00766
ER  -

TY  - JOUR
AU  - Ackermann, J.
TI  - Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background
JA  - Cancer Res.
PY  - 2005///
VL  - 65
SP  - 4005
EP  - 4011
M3  - 10.1158/0008-5472.CAN-04-2970
N1  - 10.1158/0008-5472.CAN-04-2970
UR  - http://dx.doi.org/10.1158/0008-5472.CAN-04-2970
ER  -

TY  - JOUR
AU  - Chin, L.
TI  - Essential role for oncogenic Ras in tumour maintenance
JA  - Nature
PY  - 1999///
VL  - 400
SP  - 468
EP  - 472
M3  - 10.1038/22788
N1  - 10.1038/22788
UR  - http://dx.doi.org/10.1038/22788
ER  -

TY  - JOUR
AU  - Gray-Schopfer, V. C.
AU  - da Rocha Dias, S.
AU  - Marais, R.
TI  - The role of B-RAF in melanoma
JA  - Cancer Metastasis Rev.
PY  - 2005///
VL  - 24
SP  - 165
EP  - 183
M3  - 10.1007/s10555-005-5865-1
N1  - 10.1007/s10555-005-5865-1
UR  - http://dx.doi.org/10.1007/s10555-005-5865-1
ER  -

TY  - JOUR
AU  - Sharma, A.
TI  - Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors
JA  - Cancer Res.
PY  - 2005///
VL  - 65
SP  - 2412
EP  - 2421
M3  - 10.1158/0008-5472.CAN-04-2423
N1  - 10.1158/0008-5472.CAN-04-2423
UR  - http://dx.doi.org/10.1158/0008-5472.CAN-04-2423
ER  -

TY  - JOUR
AU  - Wellbrock, C.
AU  - Marais, R.
TI  - Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation
JA  - J. Cell Biol.
PY  - 2005///
VL  - 170
SP  - 703
EP  - 708
M3  - 10.1083/jcb.200505059
N1  - 10.1083/jcb.200505059
UR  - http://dx.doi.org/10.1083/jcb.200505059
ER  -

TY  - JOUR
AU  - Goodall, J.
TI  - The Brn-2 transcription factor links activated BRAF to melanoma proliferation
JA  - Mol. Cell Biol.
PY  - 2004///
VL  - 24
SP  - 2923
EP  - 2931
M3  - 10.1128/MCB.24.7.2923-2931.2004
N1  - 10.1128/MCB.24.7.2923-2931.2004
UR  - http://dx.doi.org/10.1128/MCB.24.7.2923-2931.2004
ER  -

TY  - JOUR
AU  - Bhatt, K. V.
TI  - Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling
JA  - Oncogene
PY  - 2005///
VL  - 24
SP  - 3459
EP  - 3471
M3  - 10.1038/sj.onc.1208544
N1  - 10.1038/sj.onc.1208544
UR  - http://dx.doi.org/10.1038/sj.onc.1208544
ER  -

TY  - JOUR
AU  - Gray-Schopfer, V. C.
TI  - Cellular senescence in naevi and immortalisation in melanoma: a role for p16?
JA  - Br. J. Cancer
PY  - 2006///
VL  - 95
SP  - 496
EP  - 505
M3  - 10.1038/sj.bjc.6603283
N1  - 10.1038/sj.bjc.6603283
UR  - http://dx.doi.org/10.1038/sj.bjc.6603283
ER  -

TY  - JOUR
AU  - Michaloglou, C.
TI  - BRAFE600-associated senescence-like cell cycle arrest of human naevi
JA  - Nature
PY  - 2005///
VL  - 436
SP  - 720
EP  - 724
M3  - 10.1038/nature03890
N1  - 10.1038/nature03890
UR  - http://dx.doi.org/10.1038/nature03890
ER  -

TY  - JOUR
AU  - Huntington, J. T.
TI  - Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling
JA  - J. Biol. Chem.
PY  - 2004///
VL  - 279
SP  - 33168
EP  - 33176
M3  - 10.1074/jbc.M405102200
N1  - 10.1074/jbc.M405102200
UR  - http://dx.doi.org/10.1074/jbc.M405102200
ER  -

TY  - JOUR
AU  - Ellerhorst, J. A.
TI  - Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma
JA  - Oncogene
PY  - 2006///
VL  - 25
SP  - 3956
EP  - 3962
M3  - 10.1038/sj.onc.1209419
N1  - 10.1038/sj.onc.1209419
UR  - http://dx.doi.org/10.1038/sj.onc.1209419
ER  -

TY  - JOUR
AU  - Shaw, R. J.
AU  - Cantley, L. C.
TI  - Ras, PI(3)K and mTOR signalling controls tumour cell growth
JA  - Nature
PY  - 2006///
VL  - 441
SP  - 424
EP  - 430
M3  - 10.1038/nature04869
N1  - 10.1038/nature04869
UR  - http://dx.doi.org/10.1038/nature04869
ER  -

TY  - JOUR
AU  - Omholt, K.
AU  - Krockel, D.
AU  - Ringborg, U.
AU  - Hansson, J.
TI  - Mutations of PIK3CA are rare in cutaneous melanoma
JA  - Melanoma Res.
PY  - 2006///
VL  - 16
SP  - 197
EP  - 200
M3  - 10.1097/01.cmr.0000200488.77970.e3
N1  - 10.1097/01.cmr.0000200488.77970.e3
UR  - http://dx.doi.org/10.1097/01.cmr.0000200488.77970.e3
ER  -

TY  - JOUR
AU  - Wu, H.
AU  - Goel, V.
AU  - Haluska, F. G.
TI  - PTEN signaling pathways in melanoma
JA  - Oncogene
PY  - 2003///
VL  - 22
SP  - 3113
EP  - 3122
M3  - 10.1038/sj.onc.1206451
N1  - 10.1038/sj.onc.1206451
UR  - http://dx.doi.org/10.1038/sj.onc.1206451
ER  -

TY  - JOUR
AU  - Stahl, J. M.
TI  - Deregulated Akt3 activity promotes development of malignant melanoma
JA  - Cancer Res.
PY  - 2004///
VL  - 64
SP  - 7002
EP  - 7010
M3  - 10.1158/0008-5472.CAN-04-1399
N1  - 10.1158/0008-5472.CAN-04-1399
UR  - http://dx.doi.org/10.1158/0008-5472.CAN-04-1399
ER  -

TY  - JOUR
AU  - Smalley, K. S.
TI  - Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases
JA  - Mol. Cancer Ther.
PY  - 2006///
VL  - 5
SP  - 1136
EP  - 1144
M3  - 10.1158/1535-7163.MCT-06-0084
N1  - 10.1158/1535-7163.MCT-06-0084
UR  - http://dx.doi.org/10.1158/1535-7163.MCT-06-0084
ER  -

TY  - JOUR
AU  - Tsao, H.
AU  - Goel, V.
AU  - Wu, H.
AU  - Yang, G.
AU  - Haluska, F. G.
TI  - Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma
JA  - J. Invest. Dermatol.
PY  - 2004///
VL  - 122
SP  - 337
EP  - 341
M3  - 10.1046/j.0022-202X.2004.22243.x
N1  - 10.1046/j.0022-202X.2004.22243.x
UR  - http://dx.doi.org/10.1046/j.0022-202X.2004.22243.x
ER  -

TY  - JOUR
AU  - Wellbrock, C.
TI  - V599EB-RAF is an oncogene in melanocytes
JA  - Cancer Res.
PY  - 2004///
VL  - 64
SP  - 2338
EP  - 2342
M3  - 10.1158/0008-5472.CAN-03-3433
N1  - 10.1158/0008-5472.CAN-03-3433
UR  - http://dx.doi.org/10.1158/0008-5472.CAN-03-3433
ER  -

TY  - JOUR
AU  - Levy, C.
AU  - Khaled, M.
AU  - Fisher, D. E.
TI  - MITF: master regulator of melanocyte development and melanoma oncogene
JA  - Trends Mol. Med.
PY  - 2006///
VL  - 12
SP  - 406
EP  - 414
M3  - 10.1016/j.molmed.2006.07.008
N1  - 10.1016/j.molmed.2006.07.008
UR  - http://dx.doi.org/10.1016/j.molmed.2006.07.008
ER  -

TY  - JOUR
AU  - Selzer, E.
TI  - The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma
JA  - Cancer Res.
PY  - 2002///
VL  - 62
SP  - 2098
EP  - 2103
ER  -

TY  - JOUR
AU  - Garraway, L. A.
TI  - Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
JA  - Nature
PY  - 2005///
VL  - 436
SP  - 117
EP  - 122
M3  - 10.1038/nature03664
N1  - 10.1038/nature03664
UR  - http://dx.doi.org/10.1038/nature03664
ER  -

TY  - JOUR
AU  - Wu, M.
TI  - c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi
JA  - Genes Dev.
PY  - 2000///
VL  - 14
SP  - 301
EP  - 312
ER  -

TY  - JOUR
AU  - Takeda, K.
TI  - Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a
JA  - J. Biol. Chem.
PY  - 2000///
VL  - 275
SP  - 14013
EP  - 14016
M3  - 10.1074/jbc.C000113200
N1  - 10.1074/jbc.C000113200
UR  - http://dx.doi.org/10.1074/jbc.C000113200
ER  -

TY  - JOUR
AU  - Omholt, K.
AU  - Platz, A.
AU  - Ringborg, U.
AU  - Hansson, J.
TI  - Cytoplasmic and nuclear accumulation of [beta]-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma
JA  - Int. J. Cancer
PY  - 2001///
VL  - 92
SP  - 839
EP  - 842
M3  - 10.1002/ijc.1270
N1  - 10.1002/ijc.1270
UR  - http://dx.doi.org/10.1002/ijc.1270
ER  -

TY  - JOUR
AU  - Rimm, D. L.
AU  - Caca, K.
AU  - Hu, G.
AU  - Harrison, F. B.
AU  - Fearon, E. R.
TI  - Frequent nuclear/cytoplasmic localization of [beta]-catenin without exon 3 mutations in malignant melanoma
JA  - Am. J. Pathol.
PY  - 1999///
VL  - 154
SP  - 325
EP  - 329
ER  -

TY  - JOUR
AU  - Worm, J.
AU  - Christensen, C.
AU  - Gronbaek, K.
AU  - Tulchinsky, E.
AU  - Guldberg, P.
TI  - Genetic and epigenetic alterations of the APC gene in malignant melanoma
JA  - Oncogene
PY  - 2004///
VL  - 23
SP  - 5215
EP  - 5226
M3  - 10.1038/sj.onc.1207647
N1  - 10.1038/sj.onc.1207647
UR  - http://dx.doi.org/10.1038/sj.onc.1207647
ER  -

TY  - JOUR
AU  - Chen, D.
TI  - SKI activates Wnt/[beta]-catenin signaling in human melanoma
JA  - Cancer Res.
PY  - 2003///
VL  - 63
SP  - 6626
EP  - 6634
ER  -

TY  - JOUR
AU  - Soengas, M. S.
TI  - Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
JA  - Nature
PY  - 2001///
VL  - 409
SP  - 207
EP  - 211
M3  - 10.1038/35051606
N1  - 10.1038/35051606
UR  - http://dx.doi.org/10.1038/35051606
ER  -

TY  - GEN
AU  - Bennett, D. C.
TI  - 
PY  - 2003///
SP  - 3063
EP  - 3069
ER  -

TY  - JOUR
AU  - Hanahan, D.
AU  - Weinberg, R. A.
TI  - The hallmarks of cancer
JA  - Cell
PY  - 2000///
VL  - 100
SP  - 57
EP  - 70
M3  - 10.1016/S0092-8674(00)81683-9
N1  - 10.1016/S0092-8674(00)81683-9
UR  - http://dx.doi.org/10.1016/S0092-8674(00)81683-9
ER  -

TY  - JOUR
AU  - Serrano, M.
AU  - Hannon, G. J.
AU  - Beach, D.
TI  - A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
JA  - Nature
PY  - 1993///
VL  - 366
SP  - 704
EP  - 707
M3  - 10.1038/366704a0
N1  - 10.1038/366704a0
UR  - http://dx.doi.org/10.1038/366704a0
ER  -

TY  - JOUR
AU  - Hayward, N. K.
TI  - Genetics of melanoma predisposition
JA  - Oncogene
PY  - 2003///
VL  - 22
SP  - 3053
EP  - 3062
M3  - 10.1038/sj.onc.1206445
N1  - 10.1038/sj.onc.1206445
UR  - http://dx.doi.org/10.1038/sj.onc.1206445
ER  -

TY  - JOUR
AU  - Sharpless, E.
AU  - Chin, L.
TI  - The INK4a/ARF locus and melanoma
JA  - Oncogene
PY  - 2003///
VL  - 22
SP  - 3092
EP  - 3098
M3  - 10.1038/sj.onc.1206461
N1  - 10.1038/sj.onc.1206461
UR  - http://dx.doi.org/10.1038/sj.onc.1206461
ER  -

TY  - JOUR
AU  - Polsky, D.
AU  - Young, A. Z.
AU  - Busam, K. J.
AU  - Alani, R. M.
TI  - The transcriptional repressor of p16/Ink4a, Id1, is up-regulated in early melanomas
JA  - Cancer Res.
PY  - 2001///
VL  - 61
SP  - 6008
EP  - 6011
ER  -

TY  - JOUR
AU  - Sauter, E. R.
TI  - Cyclin D1 is a candidate oncogene in cutaneous melanoma
JA  - Cancer Res.
PY  - 2002///
VL  - 62
SP  - 3200
EP  - 3206
ER  -

TY  - JOUR
AU  - Pollock, P. M.
TI  - High frequency of BRAF mutations in nevi
JA  - Nature Genet.
PY  - 2003///
VL  - 33
SP  - 19
EP  - 20
M3  - 10.1038/ng1054
N1  - 10.1038/ng1054
UR  - http://dx.doi.org/10.1038/ng1054
ER  -

TY  - JOUR
AU  - Papp, T.
TI  - Mutational analysis of N-ras, p53, CDKN2A (p16INK4a), p14ARF, CDK4, and MC1R genes in human dysplastic melanocytic naevi
JA  - J. Med. Genet.
PY  - 2003///
VL  - 40
SP  - E14
M3  - 10.1136/jmg.40.2.e14
N1  - 10.1136/jmg.40.2.e14
UR  - http://dx.doi.org/10.1136/jmg.40.2.e14
ER  -

TY  - JOUR
AU  - Narita, M.
TI  - Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
JA  - Cell
PY  - 2003///
VL  - 113
SP  - 703
EP  - 716
M3  - 10.1016/S0092-8674(03)00401-X
N1  - 10.1016/S0092-8674(03)00401-X
UR  - http://dx.doi.org/10.1016/S0092-8674(03)00401-X
ER  -

TY  - JOUR
AU  - Soengas, M. S.
AU  - Lowe, S. W.
TI  - Apoptosis and melanoma chemoresistance
JA  - Oncogene
PY  - 2003///
VL  - 22
SP  - 3138
EP  - 3151
M3  - 10.1038/sj.onc.1206454
N1  - 10.1038/sj.onc.1206454
UR  - http://dx.doi.org/10.1038/sj.onc.1206454
ER  -

TY  - JOUR
AU  - Tarhini, A. A.
AU  - Agarwala, S. S.
TI  - Cutaneous melanoma: available therapy for metastatic disease
JA  - Dermatol. Ther.
PY  - 2006///
VL  - 19
SP  - 19
EP  - 25
M3  - 10.1111/j.1529-8019.2005.00052.x
N1  - 10.1111/j.1529-8019.2005.00052.x
UR  - http://dx.doi.org/10.1111/j.1529-8019.2005.00052.x
ER  -

TY  - JOUR
AU  - Kirkwood, J. M.
AU  - Moschos, S.
AU  - Wang, W.
TI  - Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations
JA  - Clin. Cancer Res.
PY  - 2006///
VL  - 12
SP  - 2331s
EP  - 2336s
M3  - 10.1158/1078-0432.CCR-05-2538
N1  - 10.1158/1078-0432.CCR-05-2538
UR  - http://dx.doi.org/10.1158/1078-0432.CCR-05-2538
ER  -

TY  - JOUR
AU  - Morgan, R. A.
TI  - Cancer regression in patients after transfer of genetically engineered lymphocytes
JA  - Science
PY  - 2006///
VL  - 314
SP  - 126
EP  - 129
M3  - 10.1126/science.1129003
N1  - 10.1126/science.1129003
UR  - http://dx.doi.org/10.1126/science.1129003
ER  -

TY  - JOUR
AU  - Smalley, K. S.
AU  - Eisen, T. G.
TI  - Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells
JA  - Int. J. Cancer
PY  - 2003///
VL  - 105
SP  - 165
EP  - 175
M3  - 10.1002/ijc.11064
N1  - 10.1002/ijc.11064
UR  - http://dx.doi.org/10.1002/ijc.11064
ER  -

TY  - JOUR
AU  - Wilhelm, S. M.
TI  - BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
JA  - Cancer Res.
PY  - 2004///
VL  - 64
SP  - 7099
EP  - 7109
M3  - 10.1158/0008-5472.CAN-04-1443
N1  - 10.1158/0008-5472.CAN-04-1443
UR  - http://dx.doi.org/10.1158/0008-5472.CAN-04-1443
ER  -

TY  - JOUR
AU  - Flaherty, K. T.
TI  - Chemotherapy and targeted therapy combinations in advanced melanoma
JA  - Clin. Cancer Res.
PY  - 2006///
VL  - 12
SP  - 2366s
EP  - 2370s
M3  - 10.1158/1078-0432.CCR-05-2505
N1  - 10.1158/1078-0432.CCR-05-2505
UR  - http://dx.doi.org/10.1158/1078-0432.CCR-05-2505
ER  -

TY  - JOUR
AU  - Eisen, T.
TI  - Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
JA  - Br. J. Cancer
PY  - 2006///
VL  - 95
SP  - 581
EP  - 586
M3  - 10.1038/sj.bjc.6603291
N1  - 10.1038/sj.bjc.6603291
UR  - http://dx.doi.org/10.1038/sj.bjc.6603291
ER  -

TY  - JOUR
AU  - Gray-Schopfer, V.
AU  - Karasarides, M.
AU  - Hayward, R.
AU  - Marais, R.
TI  - Tumor necrosis factor-[alpha] blocks apoptosis in melanoma cells when BRAF signaling is inhibited
JA  - Cancer Res.
PY  - 2007///
VL  - 67
SP  - 122
EP  - 129
M3  - 10.1158/0008-5472.CAN-06-1880
N1  - 10.1158/0008-5472.CAN-06-1880
UR  - http://dx.doi.org/10.1158/0008-5472.CAN-06-1880
ER  -

TY  - JOUR
AU  - Adnane, L.
AU  - Trail, P. A.
AU  - Taylor, I.
AU  - Wilhelm, S. M.
TI  - Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature
JA  - Methods Enzymol.
PY  - 2005///
VL  - 407
SP  - 597
EP  - 612
ER  -

TY  - JOUR
AU  - Garnett, M. J.
AU  - Rana, S.
AU  - Paterson, H.
AU  - Barford, D.
AU  - Marais, R.
TI  - Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization
JA  - Mol. Cell
PY  - 2005///
VL  - 20
SP  - 963
EP  - 969
M3  - 10.1016/j.molcel.2005.10.022
N1  - 10.1016/j.molcel.2005.10.022
UR  - http://dx.doi.org/10.1016/j.molcel.2005.10.022
ER  -

TY  - JOUR
AU  - Dumaz, N.
TI  - In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling
JA  - Cancer Res.
PY  - 2006///
VL  - 66
SP  - 9483
EP  - 9491
M3  - 10.1158/0008-5472.CAN-05-4227
N1  - 10.1158/0008-5472.CAN-05-4227
UR  - http://dx.doi.org/10.1158/0008-5472.CAN-05-4227
ER  -

TY  - JOUR
AU  - Collisson, E. A.
AU  - De, A.
AU  - Suzuki, H.
AU  - Gambhir, S. S.
AU  - Kolodney, M. S.
TI  - Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade
JA  - Cancer Res.
PY  - 2003///
VL  - 63
SP  - 5669
EP  - 5673
ER  -

TY  - JOUR
AU  - Solit, D. B.
TI  - BRAF mutation predicts sensitivity to MEK inhibition
JA  - Nature
PY  - 2006///
VL  - 439
SP  - 358
EP  - 362
M3  - 10.1038/nature04304
N1  - 10.1038/nature04304
UR  - http://dx.doi.org/10.1038/nature04304
ER  -

TY  - JOUR
AU  - Koo, H. M.
TI  - Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase
JA  - Proc. Natl Acad. Sci. USA
PY  - 2002///
VL  - 99
SP  - 3052
EP  - 3057
M3  - 10.1073/pnas.052707699
N1  - 10.1073/pnas.052707699
UR  - http://dx.doi.org/10.1073/pnas.052707699
ER  -

TY  - JOUR
AU  - Beinke, S.
AU  - Robinson, M. J.
AU  - Hugunin, M.
AU  - Ley, S. C.
TI  - Lipopolysaccharide activation of the TPL-2/MEK/extracellular signal-regulated kinase mitogen-activated protein kinase cascade is regulated by I[kappa]B kinase-induced proteolysis of NF-[kappa]B1 p105
JA  - Mol. Cell. Biol.
PY  - 2004///
VL  - 24
SP  - 9658
EP  - 9667
M3  - 10.1128/MCB.24.21.9658-9667.2004
N1  - 10.1128/MCB.24.21.9658-9667.2004
UR  - http://dx.doi.org/10.1128/MCB.24.21.9658-9667.2004
ER  -

TY  - JOUR
AU  - Dancey, J. E.
TI  - Therapeutic targets: MTOR and related pathways
JA  - Cancer Biol. Ther.
PY  - 2006///
VL  - 5
SP  - 1065
EP  - 1073
ER  -

TY  - JOUR
AU  - Bush, J. A.
AU  - Li, G.
TI  - The role of Bcl-2 family members in the progression of cutaneous melanoma
JA  - Clin. Exp. Metastasis
PY  - 2003///
VL  - 20
SP  - 531
EP  - 539
M3  - 10.1023/A:1025874502181
N1  - 10.1023/A:1025874502181
UR  - http://dx.doi.org/10.1023/A:1025874502181
ER  -

TY  - JOUR
AU  - Nishimura, E. K.
AU  - Granter, S. R.
AU  - Fisher, D. E.
TI  - Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche
JA  - Science
PY  - 2005///
VL  - 307
SP  - 720
EP  - 724
M3  - 10.1126/science.1099593
N1  - 10.1126/science.1099593
UR  - http://dx.doi.org/10.1126/science.1099593
ER  -

TY  - JOUR
AU  - Jansen, B.
TI  - bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
JA  - Nature Med.
PY  - 1998///
VL  - 4
SP  - 232
EP  - 234
M3  - 10.1038/nm0298-232
N1  - 10.1038/nm0298-232
UR  - http://dx.doi.org/10.1038/nm0298-232
ER  -

TY  - JOUR
AU  - Bedikian, A. Y.
TI  - Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group
JA  - J. Clin. Oncol.
PY  - 2006///
VL  - 24
SP  - 4738
EP  - 4745
M3  - 10.1200/JCO.2006.06.0483
N1  - 10.1200/JCO.2006.06.0483
UR  - http://dx.doi.org/10.1200/JCO.2006.06.0483
ER  -

TY  - JOUR
AU  - Del Bufalo, D.
AU  - Trisciuoglio, D.
AU  - Scarsella, M.
AU  - Zangemeister-Wittke, U.
AU  - Zupi, G.
TI  - Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity
JA  - Oncogene
PY  - 2003///
VL  - 22
SP  - 8441
EP  - 8447
M3  - 10.1038/sj.onc.1206999
N1  - 10.1038/sj.onc.1206999
UR  - http://dx.doi.org/10.1038/sj.onc.1206999
ER  -

TY  - JOUR
AU  - Fry, D. W.
TI  - Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
JA  - Mol. Cancer Ther.
PY  - 2004///
VL  - 3
SP  - 1427
EP  - 1438
ER  -

TY  - JOUR
AU  - Sharp, S.
AU  - Workman, P.
TI  - Inhibitors of the HSP90 molecular chaperone: current status
JA  - Adv. Cancer Res.
PY  - 2006///
VL  - 95
SP  - 323
EP  - 348
ER  -

TY  - JOUR
AU  - da Rocha Dias, S.
TI  - Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin
JA  - Cancer Res.
PY  - 2005///
VL  - 65
SP  - 10686
EP  - 10691
M3  - 10.1158/0008-5472.CAN-05-2632
N1  - 10.1158/0008-5472.CAN-05-2632
UR  - http://dx.doi.org/10.1158/0008-5472.CAN-05-2632
ER  -

TY  - JOUR
AU  - Grbovic, O. M.
TI  - V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors
JA  - Proc. Natl Acad. Sci. USA
PY  - 2006///
VL  - 103
SP  - 57
EP  - 62
M3  - 10.1073/pnas.0609973103
N1  - 10.1073/pnas.0609973103
UR  - http://dx.doi.org/10.1073/pnas.0609973103
ER  -

TY  - JOUR
AU  - Amiri, K. I.
AU  - Horton, L. W.
AU  - LaFleur, B. J.
AU  - Sosman, J. A.
AU  - Richmond, A.
TI  - Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma
JA  - Cancer Res.
PY  - 2004///
VL  - 64
SP  - 4912
EP  - 4918
M3  - 10.1158/0008-5472.CAN-04-0673
N1  - 10.1158/0008-5472.CAN-04-0673
UR  - http://dx.doi.org/10.1158/0008-5472.CAN-04-0673
ER  -

TY  - JOUR
AU  - Burke, J. R.
TI  - BMS-345541 is a highly selective inhibitor of I[kappa]B kinase that binds at an allosteric site of the enzyme and blocks NF-[kappa] B-dependent transcription in mice
JA  - J. Biol. Chem.
PY  - 2003///
VL  - 278
SP  - 1450
EP  - 1456
M3  - 10.1074/jbc.M209677200
N1  - 10.1074/jbc.M209677200
UR  - http://dx.doi.org/10.1074/jbc.M209677200
ER  -

TY  - JOUR
AU  - Rofstad, E. K.
AU  - Halsor, E. F.
TI  - Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts
JA  - Cancer Res.
PY  - 2000///
VL  - 60
SP  - 4932
EP  - 4938
ER  -

TY  - JOUR
AU  - Tucker, G. C.
TI  - Integrins: molecular targets in cancer therapy
JA  - Curr. Oncol. Rep.
PY  - 2006///
VL  - 8
SP  - 96
EP  - 103
ER  -

TY  - JOUR
AU  - Gutheil, J. C.
TI  - Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin [alpha][nu][beta]3
JA  - Clin. Cancer Res.
PY  - 2000///
VL  - 6
SP  - 3056
EP  - 3061
ER  -

TY  - JOUR
AU  - Gupta, P. B.
AU  - Mani, S.
AU  - Yang, J.
AU  - Hartwell, K.
AU  - Weinberg, R. A.
TI  - The evolving portrait of cancer metastasis
JA  - Cold Spring Harb. Symp. Quant. Biol.
PY  - 2005///
VL  - 70
SP  - 291
EP  - 297
M3  - 10.1101/sqb.2005.70.033
N1  - 10.1101/sqb.2005.70.033
UR  - http://dx.doi.org/10.1101/sqb.2005.70.033
ER  -

TY  - JOUR
AU  - Kim, M.
TI  - Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene
JA  - Cell
PY  - 2006///
VL  - 125
SP  - 1269
EP  - 1281
M3  - 10.1016/j.cell.2006.06.008
N1  - 10.1016/j.cell.2006.06.008
UR  - http://dx.doi.org/10.1016/j.cell.2006.06.008
ER  -

TY  - JOUR
AU  - Straume, O.
AU  - Akslen, L. A.
TI  - Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma
JA  - Int. J. Cancer
PY  - 1997///
VL  - 74
SP  - 535
EP  - 539
M3  - 10.1002/(SICI)1097-0215(19971021)74:5<535::AID-IJC10>3.0.CO;2-5
N1  - 10.1002/(SICI)1097-0215(19971021)74:5<535::AID-IJC10>3.0.CO;2-5
UR  - http://dx.doi.org/10.1002/(SICI)1097-0215(19971021)74:5<535::AID-IJC10>3.0.CO;2-5
ER  -

TY  - JOUR
AU  - Lee, P.
TI  - ARRY-142886, a potent and selective MEK inhibitor: III) Efficacy in murine xenograft models correlates with decreased ERK phosphorylation
JA  - Proc. Am. Assoc. Cancer Res.
PY  - 2004///
VL  - 45
SP  - 897
ER  -

TY  - JOUR
AU  - Lyssikatos, J.
TI  - ARRY-142886, a potent and selective MEK inhibitor: I) ATP-independent inhibition results in high enzymatic and cellular selectivity
JA  - Proc. Am. Assoc. Cancer Res.
PY  - 2004///
VL  - 45
SP  - 896-b
ER  -

TY  - JOUR
AU  - Yeh, T.
AU  - Wallace, E.
AU  - Lyssikatos, J.
AU  - Winkler, J.
TI  - ARRY-142886, a potent and selective MEK inhibitor: II) Potency against cellular MEK leads to inhibition of cellular proliferation and induction of apoptosis in cell lines with mutant Ras or B-Raf
JA  - Proc. Am. Assoc. Cancer Res.
PY  - 2004///
VL  - 45
SP  - 896-c
EP  - 897-c
ER  -

TY  - JOUR
AU  - Morabito, A.
AU  - De Maio, E.
AU  - Di Maio, M.
AU  - Normanno, N.
AU  - Perrone, F.
TI  - Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions
JA  - Oncologist
PY  - 2006///
VL  - 11
SP  - 753
EP  - 764
M3  - 10.1634/theoncologist.11-7-753
N1  - 10.1634/theoncologist.11-7-753
UR  - http://dx.doi.org/10.1634/theoncologist.11-7-753
ER  -

TY  - JOUR
AU  - Peterson, A. C.
TI  - Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma
JA  - Clin. Cancer Res.
PY  - 2004///
VL  - 10
SP  - 4048
EP  - 4054
M3  - 10.1158/1078-0432.CCR-03-0766
N1  - 10.1158/1078-0432.CCR-03-0766
UR  - http://dx.doi.org/10.1158/1078-0432.CCR-03-0766
ER  -

TY  - JOUR
AU  - Margolin, K.
TI  - CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium
JA  - Cancer
PY  - 2005///
VL  - 104
SP  - 1045
EP  - 1048
M3  - 10.1002/cncr.21265
N1  - 10.1002/cncr.21265
UR  - http://dx.doi.org/10.1002/cncr.21265
ER  -

TY  - JOUR
AU  - O'Donnell, A.
TI  - A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK), and pharmacodynamic (PD) endpoints in patients with solid tumors
JA  - Proc. Am. Soc. Clin. Oncol.
PY  - 2003///
VL  - 22
ER  -

TY  - JOUR
AU  - End, D. W.
TI  - Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro
JA  - Cancer Res.
PY  - 2001///
VL  - 61
SP  - 131
EP  - 137
ER  -

TY  - JOUR
AU  - Markovic, S. N.
TI  - A phase II study of bortezomib in the treatment of metastatic malignant melanoma
JA  - Cancer
PY  - 2005///
VL  - 103
SP  - 2584
EP  - 2589
M3  - 10.1002/cncr.21108
N1  - 10.1002/cncr.21108
UR  - http://dx.doi.org/10.1002/cncr.21108
ER  -

TY  - JOUR
AU  - Yang, J.
AU  - Amiri, K. I.
AU  - Burke, J. R.
AU  - Schmid, J. A.
AU  - Richmond, A.
TI  - BMS-345541 targets inhibitor of [kappa]B kinase and induces apoptosis in melanoma: involvement of nuclear factor [kappa]B and mitochondria pathways
JA  - Clin. Cancer Res.
PY  - 2006///
VL  - 12
SP  - 950
EP  - 960
M3  - 10.1158/1078-0432.CCR-05-1220
N1  - 10.1158/1078-0432.CCR-05-1220
UR  - http://dx.doi.org/10.1158/1078-0432.CCR-05-1220
ER  -

TY  - JOUR
AU  - Yaguchi, S.
TI  - Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor
JA  - J. Natl Cancer Inst.
PY  - 2006///
VL  - 98
SP  - 545
EP  - 556
ER  -